Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Dearnaley

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2024
Reply to J.A. Garcia et alSusan Halabi, Siyuan Guo, Akash Roy, et al.
The Lancet. Oncology|December 16, 2011
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis studyGillian C Barnett, Charlotte E Coles, Rebecca M Elliott, et al.
Nature Genetics|July 1, 2014
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1Laura Fachal, Antonio Gómez-Caamaño, Gillian C Barnett, et al.
Plos One|June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial dataCaroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
American Journal of Human Genetics|December 11, 2002
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 geneStephen M Edwards, Zsofia Kote-Jarai, Julia Meitz, et al.
European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Genetic Epidemiology|June 4, 2009
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studiesRobert J MacInnis, Antonis C Antoniou, Rosalind A Eeles, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2024
Reply to J.A. Garcia et alSusan Halabi, Siyuan Guo, Akash Roy, et al.
The Lancet. Oncology|December 16, 2011
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis studyGillian C Barnett, Charlotte E Coles, Rebecca M Elliott, et al.
Nature Genetics|July 1, 2014
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1Laura Fachal, Antonio Gómez-Caamaño, Gillian C Barnett, et al.
Plos One|June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial dataCaroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
American Journal of Human Genetics|December 11, 2002
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 geneStephen M Edwards, Zsofia Kote-Jarai, Julia Meitz, et al.
European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Genetic Epidemiology|June 4, 2009
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studiesRobert J MacInnis, Antonis C Antoniou, Rosalind A Eeles, et al.
Pageof 15